UB Paderborn / Katalog / Suche / in CDI

Curcumin as a clinically-promising anti-cancer agent: pharmacokinetics and drug interactions

Expert opinion on drug metabolism & toxicology, 2017-09, Vol.13 (9), p.953-972

2017

Volltextzugriff (PDF)

Implementation of a Physiologically Based Pharmacokinetic Modeling Approach to Guide Optimal Dosing Regimens for Imatinib and Potential Drug Interactions in Paediatrics

Frontiers in pharmacology, 2020-01, Vol.10, p.1672

2020

Volltextzugriff (PDF)

An LC/MS/MS method for stable isotope dilution studies of β-carotene bioavailability, bioconversion, and vitamin A status in humans[S]

Journal of lipid research, 2014-02, Vol.55 (2), p.319-328

2014

Volltextzugriff (PDF)

Phase I Study of MG98, an Oligonucleotide Antisense Inhibitor of Human DNA Methyltransferase 1, Given as a 7-Day Infusion in Patients with Advanced Solid Tumors

Clinical cancer research, 2009-05, Vol.15 (9), p.3177-3183

2009

Volltextzugriff (PDF)

Is there scope for better individualisation of anthracycline cancer chemotherapy?

British journal of clinical pharmacology, 2021-02, Vol.87 (2), p.295-305

2021

Volltextzugriff (PDF)

Physiologically-Based Pharmacokinetic Predictions of the Effect of Curcumin on Metabolism of Imatinib and Bosutinib: In Vitro and In Vivo Disconnect

Pharmaceutical research, 2020-07, Vol.37 (7), p.128, Article 128

2020

Volltextzugriff (PDF)

Inhibition of Poly(ADP-Ribose) Polymerase-1 Enhances Temozolomide and Topotecan Activity against Childhood Neuroblastoma

Clinical cancer research, 2009-02, Vol.15 (4), p.1241-1249

2009

Volltextzugriff (PDF)

Potential for pharmacokinetic interactions between Schisandra sphenanthera and bosutinib, but not imatinib: in vitro metabolism study combined with a physiologically‐based pharmacokinetic modelling approach

British journal of clinical pharmacology, 2020-10, Vol.86 (10), p.2080-2094

2020

Volltextzugriff (PDF)

Physiologically‐based pharmacokinetic model predictions of inter‐ethnic differences in imatinib pharmacokinetics and dosing regimens

British journal of clinical pharmacology, 2022-02, Vol.88 (4), p.1735-1750

2022

Volltextzugriff (PDF)

Physiologically based pharmacokinetic model predictions of natural product-drug interactions between goldenseal, berberine, imatinib and bosutinib

European journal of clinical pharmacology, 2022-04, Vol.78 (4), p.597-611

2022

Volltextzugriff (PDF)

Physiologically Based Pharmacokinetic Modelling of Hyperforin to Predict Drug Interactions with St John’s Wort

Clinical pharmacokinetics, 2019-07, Vol.58 (7), p.911-926

2019

Volltextzugriff (PDF)

Interactions between natural products and cancer treatments: underlying mechanisms and clinical importance

Cancer chemotherapy and pharmacology, 2023-02, Vol.91 (2), p.103-119

2023

Volltextzugriff (PDF)

A Phase I and Pharmacokinetic Study of Paclitaxel Poliglumex (XYOTAX), Investigating Both 3-Weekly and 2-Weekly Schedules

Clinical cancer research, 2005-11, Vol.11 (21), p.7834-7840

2005

Volltextzugriff (PDF)

Imagestream detection and characterisation of circulating tumour cells - a liquid biopsy for Hepatocellular Carcinoma?

Journal of hepatology, 2016-08, Vol.65 (2), p.305-313

2016

Volltextzugriff (PDF)

Two minor NQO1 and NQO2 alleles predict poor response of breast cancer patients to adjuvant doxorubicin and cyclophosphamide therapy

Pharmacogenetics and genomics, 2011-12, Vol.21 (12), p.808-819

2011

Volltextzugriff (PDF)

Physiologically Based Pharmacokinetic Modeling Approaches for Patients With SARS‐CoV‐2 Infection: A Case Study With Imatinib

Journal of clinical pharmacology, 2022-10, Vol.62 (10), p.1285-1296

2022

Volltextzugriff (PDF)

Phase I Clinical and Pharmacokinetic Study of Pemetrexed and Carboplatin in Patients With Malignant Pleural Mesothelioma

Journal of clinical oncology, 2002-08, Vol.20 (16), p.3533-3544

2002

Volltextzugriff (PDF)

A Retinol Isotope Dilution Equation Predicts Both Group and Individual Total Body Vitamin A Stores in Adults Based on Data from an Early Postdosing Blood Sample

The Journal of nutrition, 2016-10, Vol.146 (10), p.2137-2142

2016

Volltextzugriff (PDF)

Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin's lymphoma

European journal of cancer (1990), 2016-03, Vol.55, p.56-64

2016

Volltextzugriff (PDF)

Clinical Pharmacokinetic and Pharmacodynamic Considerations in the (Modern) Treatment of Melanoma

Clinical pharmacokinetics, 2019-08, Vol.58 (8), p.1029-1043

2019

Volltextzugriff (PDF)

Pharmacokinetic and cytokine profiles of melanoma patients with dabrafenib and trametinib-induced pyrexia

Cancer chemotherapy and pharmacology, 2019-04, Vol.83 (4), p.693-704

2019

Volltextzugriff (PDF)

Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System

Molecular cancer therapeutics, 2015-12, Vol.14 (12), p.2735-2743

2015

Volltextzugriff (PDF)

NAD(P)H:Quinone Oxidoreductase 1 and NRH:Quinone Oxidoreductase 2 Activity and Expression in Bladder and Ovarian Cancer and Lower NRH:Quinone Oxidoreductase 2 Activity Associated with an NQO2 Exon 3 Single-Nucleotide Polymorphism

Clinical cancer research, 2007-03, Vol.13 (5), p.1584-1590

2007

Volltextzugriff (PDF)

Plasma Retinol Kinetics and β-Carotene Bioefficacy Are Quantified by Model-Based Compartmental Analysis in Healthy Young Adults with Low Vitamin A Stores

The Journal of nutrition, 2016-10, Vol.146 (10), p.2129-2136

2016

Volltextzugriff (PDF)

Monte Carlo simulations of the clinical benefits from therapeutic drug monitoring of sunitinib in patients with gastrointestinal stromal tumours

Cancer chemotherapy and pharmacology, 2016-07, Vol.78 (1), p.209-216

2016

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Curcumin as a clinically-promising anti-cancer agent: pharmacokinetics and drug interactions

Implementation of a Physiologically Based Pharmacokinetic Modeling Approach to Guide Optimal Dosing Regimens for Imatinib and Potential Drug Interactions in Paediatrics

An LC/MS/MS method for stable isotope dilution studies of β-carotene bioavailability, bioconversion, and vitamin A status in humans[S]

Phase I Study of MG98, an Oligonucleotide Antisense Inhibitor of Human DNA Methyltransferase 1, Given as a 7-Day Infusion in Patients with Advanced Solid Tumors

Is there scope for better individualisation of anthracycline cancer chemotherapy?

Physiologically-Based Pharmacokinetic Predictions of the Effect of Curcumin on Metabolism of Imatinib and Bosutinib: In Vitro and In Vivo Disconnect

Inhibition of Poly(ADP-Ribose) Polymerase-1 Enhances Temozolomide and Topotecan Activity against Childhood Neuroblastoma

Potential for pharmacokinetic interactions between Schisandra sphenanthera and bosutinib, but not imatinib: in vitro metabolism study combined with a physiologically‐based pharmacokinetic modelling approach

Physiologically‐based pharmacokinetic model predictions of inter‐ethnic differences in imatinib pharmacokinetics and dosing regimens

Physiologically based pharmacokinetic model predictions of natural product-drug interactions between goldenseal, berberine, imatinib and bosutinib

Physiologically Based Pharmacokinetic Modelling of Hyperforin to Predict Drug Interactions with St John’s Wort

Interactions between natural products and cancer treatments: underlying mechanisms and clinical importance

A Phase I and Pharmacokinetic Study of Paclitaxel Poliglumex (XYOTAX), Investigating Both 3-Weekly and 2-Weekly Schedules

Imagestream detection and characterisation of circulating tumour cells - a liquid biopsy for Hepatocellular Carcinoma?

Two minor NQO1 and NQO2 alleles predict poor response of breast cancer patients to adjuvant doxorubicin and cyclophosphamide therapy

Physiologically Based Pharmacokinetic Modeling Approaches for Patients With SARS‐CoV‐2 Infection: A Case Study With Imatinib

Phase I Clinical and Pharmacokinetic Study of Pemetrexed and Carboplatin in Patients With Malignant Pleural Mesothelioma

A Retinol Isotope Dilution Equation Predicts Both Group and Individual Total Body Vitamin A Stores in Adults Based on Data from an Early Postdosing Blood Sample

Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin's lymphoma

Clinical Pharmacokinetic and Pharmacodynamic Considerations in the (Modern) Treatment of Melanoma

Pharmacokinetic and cytokine profiles of melanoma patients with dabrafenib and trametinib-induced pyrexia

Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System

NAD(P)H:Quinone Oxidoreductase 1 and NRH:Quinone Oxidoreductase 2 Activity and Expression in Bladder and Ovarian Cancer and Lower NRH:Quinone Oxidoreductase 2 Activity Associated with an NQO2 Exon 3 Single-Nucleotide Polymorphism

Plasma Retinol Kinetics and β-Carotene Bioefficacy Are Quantified by Model-Based Compartmental Analysis in Healthy Young Adults with Low Vitamin A Stores

Monte Carlo simulations of the clinical benefits from therapeutic drug monitoring of sunitinib in patients with gastrointestinal stromal tumours

Suchergebnisse filtern